InMode Ltd. $INMD Shares Sold by Yelin Lapidot Holdings Management Ltd.

Yelin Lapidot Holdings Management Ltd. reduced its stake in InMode Ltd. (NASDAQ:INMD) by 1.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 298,883 shares of the healthcare company’s stock after selling 5,469 shares during the quarter. InMode accounts for 0.8% of Yelin Lapidot Holdings Management Ltd.’s investment portfolio, making the stock its 29th biggest holding. Yelin Lapidot Holdings Management Ltd. owned about 0.47% of InMode worth $4,316,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of INMD. Allspring Global Investments Holdings LLC acquired a new stake in shares of InMode in the 1st quarter worth $192,000. Focus Partners Wealth boosted its position in shares of InMode by 31.8% during the 1st quarter. Focus Partners Wealth now owns 227,959 shares of the healthcare company’s stock worth $4,044,000 after purchasing an additional 54,948 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of InMode by 6.6% during the 1st quarter. Acadian Asset Management LLC now owns 556,413 shares of the healthcare company’s stock worth $9,858,000 after purchasing an additional 34,623 shares during the period. Principal Financial Group Inc. increased its holdings in shares of InMode by 1.9% in the 1st quarter. Principal Financial Group Inc. now owns 101,439 shares of the healthcare company’s stock valued at $1,800,000 after purchasing an additional 1,877 shares in the last quarter. Finally, Lind Value II ApS purchased a new position in InMode in the second quarter valued at about $3,930,000. Hedge funds and other institutional investors own 68.04% of the company’s stock.

InMode Stock Performance

INMD stock opened at $14.37 on Friday. The company has a 50 day moving average price of $15.07 and a two-hundred day moving average price of $14.66. The stock has a market capitalization of $908.20 million, a P/E ratio of 6.64 and a beta of 2.11. InMode Ltd. has a one year low of $13.14 and a one year high of $19.85.

InMode (NASDAQ:INMD) last announced its quarterly earnings data on Wednesday, November 5th. The healthcare company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. The business had revenue of $93.17 million during the quarter, compared to the consensus estimate of $88.05 million. InMode had a return on equity of 14.52% and a net margin of 41.04%.The business’s revenue for the quarter was down 28.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.70 earnings per share. Research analysts forecast that InMode Ltd. will post 1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on INMD. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Friday, October 10th. Wall Street Zen raised InMode from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Weiss Ratings restated a “sell (d+)” rating on shares of InMode in a research report on Wednesday, October 8th. Zacks Research upgraded shares of InMode from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Barclays cut their price objective on InMode from $24.00 to $21.00 and set an “overweight” rating for the company in a research report on Wednesday, July 30th. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.80.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.